This volume provides a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-alpha inhibitors. It is the first volume that summarizes this material for all available TNF-alpha inhibitors. Elevated levels of TNF-alpha have been demonstrated in Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, suggesting a role for TNF-alpha in their pathogenesis. The most recent preclinical and clinical data is presented in this book.
"Sinopsis" puede pertenecer a otra edición de este libro.
Over the last decade, the advent of biologic agents has greatly revolutionized therapeutic medicine in the management of chronic inflammatory diseases, such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Elucidation of the complex web of cytokine network and the roles of these cytokines in the pathogenesis of inflammatory disorders provided one of the key catalysts for the advancement of targeted biologic therapy in autoimmune and inflammatory diseases.
TNF-alpha is known to play a crucial role in the pathogenesis of many chronic inflammatory diseases. Elevated levels of TNF-alpha have been demonstrated in Crohn’s disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, suggesting a role for TNF-alpha in their pathogenesis. Although TNF-alpha plays a critical role in the activation of innate and acquired immune responses, the persistence of the immune response and inappropriate production of TNF-alpha can produce pathological changes resulting from chronic inflammation and tissue damage.
This volume provides a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-alpha inhibitors – etanercept, infliximab, and adalimumab. The most recent preclinical and clinical data is presented on this topic, which should be of interest to the preclinical researcher, the clinician, and the patient who wants to learn more about these therapies.
"Sobre este título" puede pertenecer a otra edición de este libro.
Librería: Basi6 International, Irving, TX, Estados Unidos de America
Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Nº de ref. del artículo: ABEOCT25-247095
Cantidad disponible: 1 disponibles
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
Condición: As New. Unread book in perfect condition. Nº de ref. del artículo: 4181796
Cantidad disponible: 15 disponibles
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
Condición: New. Nº de ref. del artículo: 4181796-n
Cantidad disponible: 15 disponibles
Librería: California Books, Miami, FL, Estados Unidos de America
Condición: New. Nº de ref. del artículo: I-9783764372484
Cantidad disponible: Más de 20 disponibles
Librería: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlanda
Condición: New. Editor(s): Weinberg, Jeffrey M. (St. Luke's-Roosevelt Hospital Center); Buchholz, Robin. Series: Milestones in Drug Therapy. Num Pages: 143 pages, 10 black & white illustrations, 8 black & white tables, biography. BIC Classification: MJE; MJM; MMG. Category: (P) Professional & Vocational. Dimension: 244 x 170 x 9. Weight in Grams: 382. . 2006. Hardback. . . . . Nº de ref. del artículo: V9783764372484
Cantidad disponible: 15 disponibles
Librería: Ria Christie Collections, Uxbridge, Reino Unido
Condición: New. In English. Nº de ref. del artículo: ria9783764372484_new
Cantidad disponible: Más de 20 disponibles
Librería: moluna, Greven, Alemania
Gebunden. Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Comprehensive reviews of efficacy, applications, and safety of all TNF-alpha inhibitorsFirst volume that summarizes this material for all available TNF-alpha inhibitorsPreclinical and clinical data is presentedThis volume provide. Nº de ref. del artículo: 5279640
Cantidad disponible: Más de 20 disponibles
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
Condición: New. Nº de ref. del artículo: 4181796-n
Cantidad disponible: Más de 20 disponibles
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
Condición: As New. Unread book in perfect condition. Nº de ref. del artículo: 4181796
Cantidad disponible: Más de 20 disponibles
Librería: Rarewaves.com USA, London, LONDO, Reino Unido
Hardback. Condición: New. 2006 ed. Over the last decade, the advent of biologic agents has greatly revolutionized therapeutic medicine in the management of chronic inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis. Elucidation of the complex web of cytokine network and the roles of these cytokines in the pat- genesis of inflammatory disorders provided one of the key catalysts for the advancement of targeted biologic therapy in autoimmune and inflammatory diseases. TNF-? is known to play a crucial role in the pathogenesis of many chronic inflammatory diseases. Elevated levels of TNF-? have been demonstrated in Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, sugge- ing a role for TNF-? in their pathogenesis. Although TNF-? plays a critical role in the activation of innate and acquired immune responses, the persistence of the immune response and inappropriate production of TNF-? can produce pathological changes resulting from chronic inflammation and tissue damage. The purpose of this volume is to provide a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-? inhibitors - etanercept, infliximab, and adalimumab. The initial three chapters of the volume provide a background on the field on TNF-? and its inhibition. Chapter 1 provides an introduction to TNF and reviews the pathophysiology of this cytokine. Chapter 2 then presents the h- tory of the development of TNF inhibitors. The pharmacology of these agents is reviewed in Chapter 3. Nº de ref. del artículo: LU-9783764372484
Cantidad disponible: Más de 20 disponibles